If MannKind (NASDAQ:MNKD) could say Afrezza reduces complications such as hypoglycemic events, weight gain, premature organ failure, etc., Afrezza would be one of the most successful product launches ...
MannKind (MNKD) is back in focus after presenting a broad package of Afrezza and FUROSCIX data at the American Diabetes Association’s 2026 Scientific Sessions, shortly after securing pediatric FDA ...
MannKind Corporation (NASDAQ:MNKD) is one of the Best Penny Stocks to Invest In According to Billionaires. MannKind ...
The current issue of Evidence-Based Diabetes Management explores studies and patient access issues surrounding this closely watched inhaled insulin. The current issue of Evidence-Based Diabetes ...
The U.S. Food and Drug Administration has approved a fast-acting diabetes drug called Afrezza for use by adults with Type 1 or Type 2 diabetes. The drug is inhaled into the lungs using a small inhaler ...
WESTLAKE VILLAGE, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented ...
WESTLAKE VILLAGE, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that the Afrezza® safety and pharmacokinetics study in pediatric patients is now ...
Paris and Valencia, Calif. – February 3, 2015 – Sanofi and MannKind Corporation announced today that Afrezza ® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by ...
When Sanofi announced it was returning the marketing rights for inhaled insulin Afrezza in January, doubts were cast on the future of MannKind Corp, the maker of the drug. Since then, the key question ...
It looks like Sanofi will go the "forgive and forget" route with jilted partner MannKind and its inhalable insulin Afrezza. It will forgive a boatload of debt tied to their original deal and forget it ...
Gaining access to Afrezza can mean battling with an insurer to cover it. Sometimes the first hurdle is getting a doctor to write a prescription, according to those who've been through the process. In ...
As Valencia drugmaker MannKind scrambles to replace the strategic partner it was relying on to market and distribute its Afrezza inhalable insulin treatment, diabetics who have come to rely on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results